Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple cream soothe psoriasis? new trial tests Urea-Based lotions

NCT ID NCT07545902

Symptom relief Sponsor: ICIM International S.r.l. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests two medical creams containing urea (20% and 40%) on people with mild plaque psoriasis or non-pustular palmoplantar psoriasis. Each participant applies the cream to one affected area and leaves a similar area untreated for comparison. The goal is to see if the creams reduce plaque severity after 4 or 8 weeks. The trial is small (35 people) and not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PROXERA PSOMED 20 cream (20% urea) and PROXERA PSOMED 40 gel (40% urea)
What this could lead to
If successful, these creams could offer a simple, non-prescription option to reduce psoriasis plaques and palmoplantar symptoms.
What could go wrong
This is a small, early study with only 35 people. The creams may not work better than no treatment, and results may not apply to everyone with psoriasis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PROXERA PSOMED 20 - normalizing cream, 20% urea * Diagnosis of plaque psoriasis (not palmoplantar) for at least 1 year PROXERA PSOMED 40 - intensive exfoliating gel, 40% urea * Diagnosis of non-pustular palmoplantar psoriasis for at least 1 year Common inclusion criteria: * Age 18-65 years * "Mild" psoriasis severity according to: * Psoriasis Area Severity Index (PASI) \<10 * Dermatologic Life Quality Index (DLQI) \<10 * Body Surface Area (BSA) \<10 Exclusion Criteria: * Product intolerance * Concomitant therapy with systemic immunomodulatory drugs (e.g., methotrexate, cyclosporine, apremilast) * Concomitant therapy with biologic drugs such as anti-TNFα, anti-IL17, or anti-IL23. * Concomitant topical therapy with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), vitamin D analogues, and combinations. * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-pustular palmoplantar psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis pustular psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-pustular palmoplantar psoriasis Plaque type psorisis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinica Dermatologica Dipartimento di Medicina e Scienze dell'Invecchiamento Università G. D' Annunzio

    RECRUITING

    Chieti, Italia, 66100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.